[Federal Register: October 26, 2000 (Volume 65, Number 208)]
[Notices]
[Page 64224]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr26oc00-76]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Biological Response Modifiers Advisory Committee; Notice of
Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Biological Response Modifiers Advisory
Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on November 16 and 17,
2000, 8:30 a.m. to 5:30 p.m.
Location: Holiday Inn, Versailles Ballrooms I and II, 8120
Wisconsin Ave., Bethesda, MD.
Contact Person: Gail M. Dapolito or Rosanna L. Harvey, Center
for Biologics Evaluation and Research (HFM-71), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-
0314, or FDA Advisory Committee Information Line, 1-800-741-8138
(301-443-0572 in the Washington, DC area), code 12389. Please call
the Information Line for up-to-date information on this meeting.
Agenda: On November 16 and 17, 2000, the committee will meet to
discuss the following issues related to gene therapy clinical
trials: (1) Product characterization, (2) preclinical models, and
(3) long term followup.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by November 9,
2000. Oral presentations from the public will be scheduled between
approximately 1 p.m. and 1:30 p.m. on November 16, 2000, and from 9
a.m. to 9:30 a.m. on November 17, 2000. Time allotted for each
presentation may be limited. Those desiring to make formal oral
presentations should notify the contact person before November 9,
2000, and submit a brief statement of the general nature of the
evidence or arguments they wish to present, the names and addresses
of proposed participants, and an indication of the approximate time
requested to make their presentation.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: October 18, 2000.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 00-27455 Filed 10-25-00; 8:45 am]
BILLING CODE 4160-01-F